Related Experiment Video
Updated: Sep 2, 2025
Specificity Analysis of Protein Lysine Methyltransferases Using SPOT Peptide Arrays
Published on: November 29, 2014
Protein Lysine Methyltransferase SMYD2: A Promising Small Molecule Target for Cancer Therapy
Quan Zheng1, Wen Zhang1, Guo-Wu Rao1
1College of Pharmaceutical Science, Zhejiang University of Technology, and Institute of Drug Development & Chemical Biology, Zhejiang University of Technology, Hangzhou 310014, China.
Abstract:
In epigenetic research, the abnormality of protein methylation modification is closely related to the occurrence and development of tumors, which stimulates the interest of researchers in protein methyltransferase research and the efforts to develop corresponding specific small molecule inhibitors. Currently, the protein lysine methyltransferase SMYD2 has been identified as a promising new small molecule target for cancer therapy. But its biological functions have not been fully studied and relatively few inhibitors have been reported, thus this field needs to be further explored. This perspective provides a comprehensive and systematic review of the available resources in this field, including its research status, biological structure, related substrates and methylation mechanisms, and research status of inhibitors. In addition, this perspective elaborates in detail the current challenges in this field, our insights into what needs to be done next, rational drug design of novel SMYD2 inhibitors, and foreseeable development directions in the future.
Insights
Protein lysine methyltransferase SMYD2 is a promising cancer target. Further research into its functions and inhibitors is crucial for developing novel cancer therapies.
Area of Science:
- Epigenetics
- Cancer Biology
- Pharmacology
Background:
- Abnormal protein methylation is linked to cancer development.
- SMYD2 (SET and MYND domain-containing protein 2) is a key protein methyltransferase and a potential cancer therapeutic target.
- Limited understanding of SMYD2's biological roles and few reported inhibitors necessitate further investigation.
Purpose of the Study:
- To provide a comprehensive review of SMYD2 research.
- To highlight current challenges and future directions in SMYD2 inhibitor development.
- To discuss rational drug design strategies for novel SMYD2 inhibitors.
Main Methods:
- Systematic literature review of SMYD2 research.
- Analysis of SMYD2 biological structure, substrates, and methylation mechanisms.
- Review of existing SMYD2 inhibitors and drug design approaches.
Main Results:
- SMYD2's critical role in tumorigenesis is increasingly recognized.
- The current landscape of SMYD2 inhibitors is limited but evolving.
- Understanding SMYD2's structure-function relationship is key for targeted drug discovery.
Conclusions:
- SMYD2 represents a significant target for epigenetic cancer therapy.
- Further exploration of SMYD2's biology and inhibitor development is warranted.
- Rational drug design holds promise for creating effective SMYD2-targeted cancer treatments.
Related Concept Videos
02:23Abnormal Proliferation
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:46Epigenetic Regulation
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...
02:15M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...